FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Kesimpta (ofatumumab) from Novartis, approving a change to the product's labeling/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

SUPPL AP for KESIMPTA (OFATUMUMAB)